Sandouka Sereen, Saadi Aseel, Singh Prince Kumar, Olowe Rhoda, Shekh-Ahmad Tawfeeq
The Institute for Drug Research, The School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, 91120, Jerusalem, Israel.
Cell Biosci. 2023 Jan 4;13(1):3. doi: 10.1186/s13578-022-00951-y.
Drug resistance is a particular problem in patients with temporal lobe epilepsy, where seizures originate mainly from the hippocampus. Many of these epilepsies are acquired conditions following an insult to the brain such as a prolonged seizure. Such conditions are characterized by pathophysiological mechanisms including massive oxidative stress that synergistically mediate the secondary brain damage, contributing to the development of epilepsy. The transcription factor nuclear factor (erythroid-derived 2)-like 2 (Nrf2) has emerged in recent years as an attractive therapeutic approach targeting to upregulate the antioxidative defenses in the cell, to ameliorate the oxidative stress-induced damage. Thus, it is important to understand the characteristics of Nrf2 activation during epileptogenesis and epilepsy. Here, we studied the temporal, regional, and cell-type specific expression of Nrf2 in the brain, in a rat model of temporal lobe epilepsy.
Early after status-epilepticus, Nrf2 is mainly activated in the hippocampus and maintained during the whole period of epileptogenesis. Only transient expression of Nrf2 was observed in the cortex. Nevertheless, the expression of several Nrf2 antioxidant target genes was increased within 24 h after status-epilepticus in both the cortex and the hippocampus. We demonstrated that after status-epilepticus in rats, Nrf2 is predominantly expressed in neurons in the CA1 and CA3 regions of the hippocampus, and only astrocytes in the CA1 increase their Nrf2 expression.
In conclusion, our data identify previously unrecognized spatial and cell-type dependent activation of Nrf2 during epilepsy development, highlighting the need for a time-controlled, and cell-type specific activation of the Nrf2 pathway for mediating anti-oxidant response after brain insult, to modify the development of epilepsy.
耐药性是颞叶癫痫患者的一个特殊问题,其癫痫发作主要起源于海马体。这些癫痫中有许多是在脑部受到损伤(如长时间癫痫发作)后获得的病症。此类病症的特征在于病理生理机制,包括大量氧化应激,其协同介导继发性脑损伤,促进癫痫的发展。转录因子核因子(红系衍生2)样2(Nrf2)近年来已成为一种有吸引力的治疗方法,旨在上调细胞内的抗氧化防御,减轻氧化应激诱导的损伤。因此,了解癫痫发生和癫痫过程中Nrf2激活的特征非常重要。在此,我们在颞叶癫痫大鼠模型中研究了大脑中Nrf2的时间、区域和细胞类型特异性表达。
癫痫持续状态后早期,Nrf2主要在海马体中被激活,并在癫痫发生的整个过程中维持。仅在皮质中观察到Nrf2的短暂表达。然而,癫痫持续状态后24小时内,皮质和海马体中几种Nrf2抗氧化靶基因的表达均增加。我们证明,大鼠癫痫持续状态后,Nrf2主要在海马体CA1和CA3区域的神经元中表达,并且只有CA1中的星形胶质细胞增加其Nrf2表达。
总之,我们的数据确定了癫痫发展过程中Nrf2先前未被认识到的空间和细胞类型依赖性激活,强调了在脑损伤后介导抗氧化反应时,需要对Nrf2途径进行时间控制和细胞类型特异性激活,以改变癫痫的发展。